Dollars for Docs lists the following 10 drugs for which companies paid the most in payments to physicians last year:
1. Xarelto (a blood thinner) — $28.4 million
2. Humira (rheumatoid arthritis drug) — $24.9 million
3. Invokana (drug for diabetes) — $20.9 million
4. Viekira (hepatitis C drug) — $19.2 million
5. Eliquis (blood thinner) — $18.8 million
6. Bydureon (diabetes drug) — $18.5 million
7. Androgel (testosterone drug)— $15.3 million
8. Synthroid (thyroid drug)—$14.7 million
9. Lupron (synthetic hormone) — $14.3 million
10. Victoza (diabetes drug)— $11.9 million
More articles on quality & infection control:
The Joint Commission addresses confusion surrounding provider text messaging: 5 things to know
Global disposable syringes market to surge to $9.9B by 2024: 4 points
Study: ’32k fewer patients would die every year if male physicians could achieve the same outcomes as female physicians’
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
